- Not a whole lot here that interested me, was hoping for comment relevant to Follow on biologics FOBs aka biosimilars, and info about mipomersen with Isis Pharma (click here for ISIS research page with more info)
- See the Past Events page for webcast link and notes from other presentations at the GS conference
- Speaker - Hanspeter Spek, President, Global Operations
- Company has undergone major reorganization, major readjustment of strategy last 2.5 yrs
- GENZ deal - derisking by going into these segments. will leave them as stand alone...patient centric approach to rare disease market will be protected
- but genzyme got into trouble, mostly because of costs and manufacturing issues (made them cut short on geographic investment, so now little presence in markets like russia, india, china...here they will benefit from SNY's prior sucesses and footrprint)
- lovenox growing in emerging markets by 17% 1q2011
RSS Feed
